A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics
Posted: 1 Apr 2009
Date Written: March 31, 2009
Abstract
In this note we critique the Brill analysis for proper data exclusivity periods for innovator biologics.
Keywords: Follow on Biologics, Data Exclusivity, Biotech Financial Risk
JEL Classification: I11, K00
Suggested Citation: Suggested Citation
Vernon, John A. and Golec, Joseph, A Response to the Brill Analysis for Proper Data Exclusivity Periods for Innovator Biologics (March 31, 2009). Available at SSRN: https://ssrn.com/abstract=1371020 or http://dx.doi.org/10.2139/ssrn.1371020
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.